# US 2024/0197851 A1 · A vaccine for protection against streptococcus suis serotype 9, sequence type 16

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197851 A1
- Document ID: US20240197851A1
- Status: Published application
- Kind: A1
- Application number: 17/909,917
- Filed: 2021-03-12
- Published: 2024-06-20
- Earliest claimed: 2020-03-14
- Assignees: Intervet Inc.
- Applicants: Intervet Inc.
- Inventors: Antonius Arnoldus Christiaan Jacobs
- Web page: https://patentgrep.com/patent/US20240197851A1

## CPC

- A61K 39/092: {Streptococcus}
- A61P 31/04: Antibacterial agents
- A61P 37/04: Immunostimulants
- C12N 9/52: derived from bacteria {or Archaea}
- A61K 2039/521: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/58: {raising an immune response against a target which is not the antigen used for immunisation}
- A61K 2039/70: {Multivalent vaccine}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention pertains to a vaccine comprising in combination an IgM protease antigen of Streptococcus suis and a Streptococcus suis bacterin of serotype (9), sequence type (16), for use in a method for protecting pigs against a pathogenic infection with Streptococcus suis serotype (9), sequence type (16).

## Claims

### Claim 1

A method for protecting pigs against a pathogenic infection with Streptococcus suis serotype 9, sequence type 16 comprising administering to a pig a combination of an IgM protease antigen of Streptococcus suis and a Streptococcus suis bacterin serotype 9, sequence type 16.

### Claim 2 (depends on 1)

The method of claim 1, wherein the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin are comprised in a single composition for administration to the pigs.

### Claim 3 (depends on 1)

The method of claim 1, wherein the IgM protease antigen of Streptococcus suis is an IgM protease of Streptococcus suis serotype 2.

### Claim 4 (depends on 1)

The method of claim 1, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin to the pigs at an age of at most 35 days.

### Claim 5 (depends on 1)

The method of claim 1, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin before an age at which the pigs are weaned.

### Claim 6

A kit-of-parts comprising in combination an IgM protease antigen of Streptococcus suis, a Streptococcus suis bacterin serotype 9, sequence type 16, and a pharmaceutically acceptable carrier.

### Claim 7

A unitary vaccine composition comprising in combination an IgM protease antigen of Streptococcus suis, a Streptococcus suis bacterin serotype 9, sequence type 16, and a pharmaceutically acceptable carrier.

### Claim at position 8

8-11. (canceled)

### Claim 12 (depends on 2)

The method of claim 2, wherein the IgM protease antigen of Streptococcus suis is an IgM protease of Streptococcus suis serotype 2.

### Claim 13 (depends on 12)

The method of claim 12, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin to the pigs at an age of at most 35 days.

### Claim 14 (depends on 3)

The method of claim 3, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin to the pigs at an age of at most 35 days.

### Claim 15 (depends on 14)

The method of claim 14, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin before an age at which the pigs are weaned.

### Claim 16 (depends on 13)

The method of claim 13, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin before an age at which the pigs are weaned.

### Claim 17 (depends on 12)

The method of claim 12, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin before an age at which the pigs are weaned.

### Claim 18 (depends on 4)

The method of claim 4, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin before an age at which the pigs are weaned.

### Claim 19 (depends on 3)

The method of claim 3, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin before an age at which the pigs are weaned.

### Claim 20 (depends on 2)

The method of claim 2, wherein the method comprises administering the IgM protease antigen of Streptococcus suis and the Streptococcus suis bacterin before an age at which the pigs are weaned.
